Cardinal Health Inc. logo

Cardinal Health Inc. (CAH)

Market Closed
5 Dec, 20:00
NYSE NYSE
$
198. 83
-0.36
-0.18%
$
50.64B Market Cap
164.74 P/E Ratio
2.02% Div Yield
1,708,343 Volume
5.74 Eps
$ 199.19
Previous Close
Day Range
198.1 200.22
Year Range
114.6 214.93
Want to track CAH and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 53 days
Seeking Clues to Cardinal (CAH) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics

Seeking Clues to Cardinal (CAH) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics

Beyond analysts' top -and-bottom-line estimates for Cardinal (CAH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.

Zacks | 1 year ago
Cardinal Health (CAH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Cardinal Health (CAH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 1 year ago
Cardinal Health (CAH) Beats Stock Market Upswing: What Investors Need to Know

Cardinal Health (CAH) Beats Stock Market Upswing: What Investors Need to Know

Cardinal Health (CAH) closed at $99.52 in the latest trading session, marking a +1.18% move from the prior day.

Zacks | 1 year ago
Cardinal Health: Growth Headwinds Ahead

Cardinal Health: Growth Headwinds Ahead

Cardinal Health's recent dividend raise (about 1%) reflects growth pressure ahead. With a ~13x P/E, valuation seems reasonable on the surface. However, when adjusted for growth, the current valuation points to an unfavorable return profile.

Seekingalpha | 1 year ago
Cardinal Health (CAH) Rises But Trails Market: What Investors Should Know

Cardinal Health (CAH) Rises But Trails Market: What Investors Should Know

Cardinal Health (CAH) reachead $100.83 at the closing of the latest trading day, reflecting a +0.57% change compared to its last close.

Zacks | 1 year ago
Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term

Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 1 year ago
Cardinal Health (CAH) Rises As Market Takes a Dip: Key Facts

Cardinal Health (CAH) Rises As Market Takes a Dip: Key Facts

In the most recent trading session, Cardinal Health (CAH) closed at $96.71, indicating a +0.91% shift from the previous trading day.

Zacks | 1 year ago
Why the Market Dipped But Cardinal Health (CAH) Gained Today

Why the Market Dipped But Cardinal Health (CAH) Gained Today

In the closing of the recent trading day, Cardinal Health (CAH) stood at $95.84, denoting a +0.44% change from the preceding trading day.

Zacks | 1 year ago
Cardinal Health's (CAH) China Syringe Makers Face FDA Warnings

Cardinal Health's (CAH) China Syringe Makers Face FDA Warnings

FDA investigations into Cardinal Health's (CAH) China-based syringe manufacturers, Jiangsu Shenli and Jiangsu Caina, reveal significant quality violations, prompting recalls and import alerts.

Zacks | 1 year ago
Why the Market Dipped But Cardinal Health (CAH) Gained Today

Why the Market Dipped But Cardinal Health (CAH) Gained Today

Cardinal Health (CAH) closed at $95.97 in the latest trading session, marking a +0.59% move from the prior day.

Zacks | 1 year ago
Cardinal Health (CAH) Stock Sinks As Market Gains: Here's Why

Cardinal Health (CAH) Stock Sinks As Market Gains: Here's Why

Cardinal Health (CAH) concluded the recent trading session at $93.74, signifying a -0.38% move from its prior day's close.

Zacks | 1 year ago
Reasons to Retain Cardinal Health (CAH) in Your Portfolio Now

Reasons to Retain Cardinal Health (CAH) in Your Portfolio Now

Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.

Zacks | 1 year ago
Loading...
Load More